Market context for this story
Loading quotes…
Informational only — not investment advice. Full markets →
Barry, OppHub America Desk · · Source: sec-edgar-current
Scribe Therapeutics ($SCTX) Insider Behzad Aghazadeh Buys Stock
💡 Monitor future insider purchases of $SCTX by Behzad Aghazadeh or other directors for sustained confidence.,Observe Scribe Therapeutics ($SCTX) earnings reports for operational performance that might align with insider sentiment.,Evaluate trading volumes and price action of $SCTX to see if the market reacts to significant insider buying.
Scribe Therapeutics·$SCTXBehzad Aghazadeh, a director and 10% owner of Scribe Therapeutics ($SCTX), made multiple significant open-market stock purchases totaling over 2.3 million shares in late July. These transactions occurred as the company’s common stock traded between $15 and $22.31.
The trade: Director and 10% owner Behzad Aghazadeh acquired 2,333,333 shares at $15, an additional 50,000 shares at $22.31, and 7,905 shares at $18.25 during the last week of July 2026. These were open-market or private purchases (code P).
Who: This activity involves Behzad Aghazadeh, a director and significant owner of Scribe Therapeutics, Inc.
Ticker: $SCTX
Signal read: Open-market purchases by company insiders, particularly those with a significant ownership stake like a 10% owner, can indicate their confidence in the company's future prospects. Such actions suggest insiders believe the stock is undervalued or poised for growth.
What to watch: U.S. investors should monitor future Form 4 filings from Aghazadeh and other insiders for additional purchase activity, which could signal a continuing positive outlook. Any cluster buying among multiple insiders or upcoming company announcements, particularly earnings reports, may further shed light on the rationale behind these acquisitions.
Based on reporting from sec-edgar-current.
Read the full story
Original reporting and related coverage — attribution links only, not paid recommendations.
Trade this story
Robinhood
Webull
Tradier
IBKR
Chart this story
TradingView
Broker and exchange buttons use invite / refer-a-friend links (rewards may be capped). Charting links (TradingView) are partner offers that may pay OppHub America a commission at no extra cost to you.
OppSHOP
Full OppSHOP →Curated tools and reads — shopping here helps keep OppHub America free.
Story playbook
A pre-built map of what to watch — stocks, ETFs, and educational next steps. Not personalized advice.
Snapshot date: July 28, 2026 at 9:58 PM ET
This playbook was built when the story published and is not live-updated. Prices, news, and risk can change after this date — treat it as a starting map, not a current trade ticket.
Story → money map
Biotech Insider Buying
A company insider spent a large amount of money buying millions of shares of Scribe Therapeutics stock. Investors care about this because insiders usually buy more stock when they believe the company is going to do well.
What changed
A major director and 10% owner acquired over 2.3 million shares of Scribe Therapeutics in open-market transactions.
Who wins / who loses
Scribe Therapeutics and its shareholders benefit from a strong vote of confidence, while short sellers or skeptics face higher near-term risk.
Time horizon
Think in terms of the next few months.
Confidence & best fit
medium confidence · Long-term investor
Safer theme exposure (ETFs)
Baskets that own the theme without betting on one company.
Single stocks (higher risk)
Primary = closest to the story · Peers = same industry · Second-order = knock-on effects · Avoid = looks related but may be a trap
Primary
- $SCTXWatch — track, don’t rush
The main company in the news had a major boss buy millions of dollars of its stock, which usually means they expect good news.
View $SCTX chart → · End-of-day delayed data
Options (education only)
No strikes or expiries — a framework for how traders might express the view. Options can expire worthless.
Beginners should skip options here because biotech stocks can move wildly based on news, making it very easy to lose money.
See options-friendly brokers →Income / OppHub America angle
Not a trade tip — ways to use the insight outside the market.
- Track Form 4 filings on the SEC website for any additional insider buying by other Scribe Therapeutics executives.
What would break this thesis
- Subsequent insider selling by the same director or disappointing clinical and earnings results.
What to do next on OppHub America
Saved playbooks stay on this device for now.
Important
Not financial advice. OppHub America playbooks are educational market maps only — not recommendations to buy, sell, or hold any security. Markets move fast; information can be wrong or outdated. Trade and invest at your own risk. Do your own research or consult a licensed advisor.